Symbols / IBRX $8.82 +3.04%
IBRX Chart
About
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.07B |
| Enterprise Value | 9.67B | Income | -351.40M | Sales | 113.29M |
| Book/sh | -0.49 | Cash/sh | 0.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 684 | IPO | — |
| P/E | — | Forward P/E | -441.00 | PEG | — |
| P/S | 80.04 | P/B | -17.82 | P/C | — |
| EV/EBITDA | -40.19 | EV/Sales | 85.36 | Quick Ratio | 4.62 |
| Current Ratio | 5.10 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.38 | EPS next Y | -0.02 | EPS Growth | — |
| Revenue Growth | 4.07% | Earnings | 2026-05-11 | ROA | -36.17% |
| ROE | — | ROIC | — | Gross Margin | 99.33% |
| Oper. Margin | -168.95% | Profit Margin | 0.00% | Shs Outstand | 1.03B |
| Shs Float | 379.46M | Short Float | 35.41% | Short Ratio | 3.55 |
| Short Interest | — | 52W High | 12.43 | 52W Low | 1.83 |
| Beta | -0.08 | Avg Volume | 36.92M | Volume | 17.69M |
| Target Price | $14.80 | Recom | Strong_buy | Prev Close | $8.56 |
| Price | $8.82 | Change | 3.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.80
Mean price target
2. Current target
$8.82
Latest analyst target
3. DCF / Fair value
$-3.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.82
Low
$11.00
High
$23.00
Mean
$14.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-09 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-03-04 | reit | Piper Sandler | Overweight → Overweight | $12 |
| 2026-02-23 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-02-23 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-02-19 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-02-17 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-26 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2026-01-23 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-23 | main | BTIG | Buy → Buy | $9 |
| 2026-01-20 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2026-01-20 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-16 | main | D. Boral Capital | Buy → Buy | $24 |
| 2026-01-13 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-16 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-12 | main | Jefferies | Buy → Buy | $9 |
| 2025-12-12 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-12-11 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-11-13 | main | D. Boral Capital | Buy → Buy | $24 |
| 2025-11-05 | main | D. Boral Capital | Buy → Buy | $24 |
- Bladder cancer guidelines add ImmunityBio combo for BCG-unresponsive cases - Stock Titan ue, 17 Mar 2026 11
- Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Yahoo Finance Mon, 16 Mar 2026 01
- Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis Wed, 18 Mar 2026 00
- IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits hu, 05 Mar 2026 06
- ImmunityBio (NASDAQ:IBRX) Shares Up 3% - Should You Buy? - MarketBeat hu, 19 Mar 2026 21
- IBRX Stock Jumps on Progress in NK Cell Therapy Production - Zacks Investment Research Mon, 16 Mar 2026 17
- $IBRX stock is down 3% today. Here's what we see in our data. - Quiver Quantitative Mon, 16 Mar 2026 19
- Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st hu, 19 Mar 2026 10
- Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist ue, 17 Mar 2026 13
- IBRX Stock Jumps on Progress in NK Cell Therapy Production - Yahoo Finance Mon, 16 Mar 2026 17
- IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins - Stocktwits Mon, 16 Mar 2026 22
- ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3% - Here's Why - MarketBeat Wed, 18 Mar 2026 21
- FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan Mon, 09 Mar 2026 07
- IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s Use - Retail Expects Sales To Surge - Stocktwits ue, 17 Mar 2026 16
- IBRX Stock: Anktiva's Approvals and What Comes Next - Yahoo Finance Fri, 13 Mar 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 75000 | 900788.0 | — | Sale at price 12.01 per share. | SIMON BARRY J. M.D. | Director | — | 2026-02-24 00:00:00 | D |
| 1 | 175000 | 1783602.0 | — | Sale at price 9.25 - 10.25 per share. | SIMON BARRY J. M.D. | Director | — | 2026-02-23 00:00:00 | D |
| 2 | 25000 | 250000.0 | — | Sale at price 10.00 per share. | SELECKY CHRISTOBEL E. | Director | — | 2026-02-23 00:00:00 | D |
| 3 | 25000 | 74500.0 | — | Conversion of Exercise of derivative security at price 2.98 per share. | SELECKY CHRISTOBEL E. | Director | — | 2026-02-23 00:00:00 | D |
| 4 | 15243 | nan | — | — | SIMON BARRY J. M.D. | Director | — | 2026-02-20 00:00:00 | D |
| 5 | 152439 | nan | — | — | ADCOCK RICHARD | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
| 6 | 40650 | nan | — | — | SACHS DAVID C | Chief Financial Officer | — | 2026-02-20 00:00:00 | D |
| 7 | 4065 | nan | — | — | LAUER REGAN J | Officer | — | 2026-02-20 00:00:00 | D |
| 8 | 114329 | nan | — | — | SOON-SHIONG PATRICK | Officer, Director and Beneficial Owner | — | 2026-02-20 00:00:00 | D |
| 9 | 274122 | nan | — | — | ADCOCK RICHARD | Chief Executive Officer | — | 2026-02-10 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -3.30K | 1.47M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.21 |
| NormalizedEBITDA | -282.76M | -303.36M | -430.36M | -358.86M |
| TotalUnusualItems | 59.20M | 39.01M | -48.22M | 6.98M |
| TotalUnusualItemsExcludingGoodwill | 59.20M | 39.01M | -48.22M | 6.98M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -351.40M | -413.56M | -583.20M | -416.57M |
| ReconciledDepreciation | 15.53M | 17.55M | 18.51M | 18.26M |
| ReconciledCostOfRevenue | 753.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -223.56M | -264.35M | -478.58M | -351.88M |
| EBIT | -239.08M | -281.90M | -497.09M | -370.14M |
| NetInterestIncome | -109.84M | -151.93M | -128.34M | -60.81M |
| InterestExpense | 112.53M | 131.74M | 86.80M | 47.15M |
| InterestIncome | 2.69M | 2.40M | 863.00K | 2.71M |
| NormalizedIncome | -410.60M | -452.57M | -534.98M | -422.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -351.40M | -413.56M | -583.20M | -416.57M |
| TotalExpenses | 369.31M | 358.93M | 361.99M | 350.86M |
| TotalOperatingIncomeAsReported | -256.03M | -344.18M | -362.25M | -351.30M |
| DilutedAverageShares | 919.86M | 700.44M | 508.64M | 399.90M |
| BasicAverageShares | 919.86M | 697.31M | 508.64M | 399.90M |
| DilutedEPS | -0.38 | -0.62 | -1.15 | -1.04 |
| BasicEPS | -0.38 | -0.59 | -1.15 | -1.04 |
| DilutedNIAvailtoComStockholders | -351.40M | -413.56M | -583.20M | -416.57M |
| NetIncomeCommonStockholders | -351.40M | -413.56M | -583.20M | -416.57M |
| NetIncome | -351.40M | -413.56M | -583.20M | -416.57M |
| MinorityInterests | 74.00K | 81.00K | 656.00K | 753.00K |
| NetIncomeIncludingNoncontrollingInterests | -351.47M | -413.64M | -583.85M | -417.32M |
| NetIncomeContinuousOperations | -351.47M | -413.64M | -583.85M | -417.32M |
| TaxProvision | -135.00K | 0.00 | -40.00K | 34.00K |
| PretaxIncome | -351.61M | -413.64M | -583.89M | -417.29M |
| OtherIncomeExpense | 14.26M | 82.46M | -94.19M | -5.86M |
| OtherNonOperatingIncomeExpenses | -44.95M | 43.46M | -38.43M | -736.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | -886.00K | -681.00K |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 886.00K | 681.00K |
| SecuritiesAmortization | -1.84M | 1.49M | 488.00K | |
| EarningsFromEquityInterest | 0.00 | 0.00 | -7.55M | -12.11M |
| GainOnSaleOfSecurity | 59.20M | 39.01M | -47.33M | 7.66M |
| NetNonOperatingInterestIncomeExpense | -109.84M | -151.93M | -128.34M | -60.81M |
| TotalOtherFinanceCost | 22.59M | 42.40M | 16.37M | |
| InterestExpenseNonOperating | 112.53M | 131.74M | 86.80M | 47.15M |
| InterestIncomeNonOperating | 2.69M | 2.40M | 863.00K | 2.71M |
| OperatingIncome | -256.03M | -344.18M | -361.36M | -350.62M |
| OperatingExpense | 368.56M | 358.93M | 361.99M | 350.86M |
| ResearchAndDevelopment | 218.56M | 190.14M | 232.37M | 248.15M |
| SellingGeneralAndAdministration | 150.00M | 168.78M | 129.62M | 102.71M |
| GrossProfit | 112.53M | 14.74M | 622.00K | 240.00K |
| CostOfRevenue | 753.00K | 0.00 | 0.00 | 0.00 |
| TotalRevenue | 113.29M | 14.74M | 622.00K | 240.00K |
| OperatingRevenue | 112.98M | 14.15M | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 163.80K | 163.80K | 163.80K | 163.80K |
| OrdinarySharesNumber | 1.01B | 852.90M | 670.87M | 421.57M |
| ShareIssued | 1.01B | 853.07M | 671.03M | 421.73M |
| NetDebt | 388.76M | 318.45M | 416.08M | 568.53M |
| TotalDebt | 518.08M | 504.17M | 726.72M | 723.77M |
| TangibleBookValue | -514.42M | -505.03M | -604.08M | -467.33M |
| InvestedCapital | -23.38M | -27.22M | 94.55M | 225.84M |
| WorkingCapital | 253.12M | 129.64M | 235.80M | -360.28M |
| NetTangibleAssets | -514.42M | -505.03M | -604.08M | -467.33M |
| CapitalLeaseObligations | 40.98M | 42.29M | 45.19M | 50.60M |
| CommonStockEquity | -500.47M | -489.10M | -586.99M | -447.33M |
| TotalCapitalization | -23.38M | -27.22M | 94.55M | -206.06M |
| TotalEquityGrossMinorityInterest | -499.57M | -488.13M | -585.94M | -449.82M |
| MinorityInterest | 895.00K | 969.00K | 1.05M | -2.49M |
| StockholdersEquity | -500.47M | -489.10M | -586.99M | -447.33M |
| GainsLossesNotAffectingRetainedEarnings | 28.96M | 1.20M | 10.00K | 183.00K |
| OtherEquityAdjustments | 28.96M | 1.20M | 10.00K | 183.00K |
| RetainedEarnings | -3.73B | -3.38B | -2.96B | -2.38B |
| AdditionalPaidInCapital | 3.20B | 2.88B | 2.37B | 1.93B |
| CapitalStock | 101.00K | 85.00K | 67.00K | 42.00K |
| CommonStock | 101.00K | 85.00K | 67.00K | 42.00K |
| TotalLiabilitiesNetMinorityInterest | 1.00B | 871.06M | 1.09B | 812.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 939.72M | 816.12M | 1.03B | 311.31M |
| OtherNonCurrentLiabilities | 325.04M | 284.72M | 156.52M | 457.00K |
| DerivativeProductLiabilities | 104.14M | 34.70M | 154.10M | 21.64M |
| NonCurrentDeferredLiabilities | 162.00K | |||
| NonCurrentDeferredTaxesLiabilities | 162.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 510.54M | 496.70M | 721.48M | 289.22M |
| LongTermCapitalLeaseObligation | 33.45M | 34.82M | 39.94M | 47.95M |
| LongTermDebt | 477.09M | 461.88M | 681.54M | 241.27M |
| CurrentLiabilities | 61.75M | 54.94M | 58.28M | 500.86M |
| OtherCurrentLiabilities | 3.07M | 1.05M | 716.00K | 1.63M |
| CurrentDebtAndCapitalLeaseObligation | 7.54M | 7.47M | 5.24M | 434.55M |
| CurrentCapitalLeaseObligation | 7.54M | 7.47M | 5.24M | 2.65M |
| CurrentDebt | 431.90M | 299.24M | ||
| OtherCurrentBorrowings | 431.90M | 299.24M | ||
| CurrentNotesPayable | 299.24M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 20.07M | 15.03M | 17.59M | 18.11M |
| PayablesAndAccruedExpenses | 31.08M | 31.40M | 34.73M | 46.57M |
| CurrentAccruedExpenses | 23.70M | 24.50M | 24.40M | 22.09M |
| Payables | 7.38M | 6.90M | 10.33M | 24.48M |
| DuetoRelatedPartiesCurrent | 403.00K | 173.00K | 1.14M | 3.47M |
| AccountsPayable | 6.98M | 6.72M | 9.20M | 21.02M |
| TotalAssets | 501.90M | 382.93M | 504.45M | 362.36M |
| TotalNonCurrentAssets | 187.02M | 198.35M | 210.37M | 221.78M |
| OtherNonCurrentAssets | 18.42M | 4.83M | 2.88M | 4.86M |
| NonCurrentNoteReceivables | 7.38M | 7.13M | 6.88M | 6.63M |
| InvestmentsAndAdvances | 0.00 | 891.00K | 840.00K | 7.60M |
| OtherInvestments | 4.86M | 6.78M | ||
| InvestmentinFinancialAssets | 0.00 | 891.00K | 840.00K | 822.00K |
| AvailableForSaleSecurities | 891.00K | 840.00K | 822.00K | |
| LongTermEquityInvestment | 840.00K | 822.00K | ||
| GoodwillAndOtherIntangibleAssets | 13.95M | 15.93M | 17.09M | 20.00M |
| OtherIntangibleAssets | 13.04M | 15.02M | 17.09M | 20.00M |
| Goodwill | 910.00K | 910.00K | ||
| NetPPE | 147.27M | 170.46M | 182.62M | 189.45M |
| AccumulatedDepreciation | -112.48M | -99.59M | -84.38M | -69.25M |
| GrossPPE | 259.76M | 270.05M | 267.00M | 258.70M |
| Leases | 73.14M | 73.13M | 72.55M | 68.71M |
| ConstructionInProgress | 86.43M | 86.42M | 84.44M | 72.69M |
| OtherProperties | 96.27M | 106.94M | 106.46M | 113.73M |
| MachineryFurnitureEquipment | 3.92M | 3.56M | 3.56M | 3.56M |
| BuildingsAndImprovements | 0.00 | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 314.88M | 184.59M | 294.08M | 140.58M |
| OtherCurrentAssets | 2.13M | 1.30M | 2.62M | 2.90M |
| PrepaidAssets | 26.39M | 22.55M | 21.83M | 28.60M |
| Inventory | 910.00K | 8.27M | 0.00 | |
| FinishedGoods | 767.00K | 0.00 | ||
| WorkInProcess | 7.50M | 0.00 | ||
| RawMaterials | 0.00 | 0.00 | ||
| Receivables | 42.62M | 2.65M | 3.17M | 1.89M |
| OtherReceivables | 1.15M | |||
| DuefromRelatedPartiesCurrent | 46.00K | 293.00K | 2.02M | 1.89M |
| AccountsReceivable | 42.57M | 2.36M | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 242.82M | 149.81M | 266.46M | 107.18M |
| OtherShortTermInvestments | 154.48M | 6.38M | 1.01M | 2.54M |
| CashAndCashEquivalents | 88.33M | 143.43M | 265.45M | 104.64M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -309.19M | -398.12M | -397.34M | -436.90M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -28.00K | -64.00K | -77.00K | -58.00K |
| IssuanceOfDebt | 2.88M | 0.00 | 258.70M | 174.12M |
| IssuanceOfCapitalStock | 400.56M | 111.36M | 100.56M | 60.43M |
| CapitalExpenditure | -4.25M | -6.89M | -30.58M | -99.39M |
| InterestPaidSupplementalData | 71.32M | 92.32M | 77.19M | 35.44M |
| IncomeTaxPaidSupplementalData | 0.00 | 15.00K | 8.00K | 2.00K |
| EndCashPosition | 89.43M | 143.91M | 265.79M | 104.97M |
| BeginningCashPosition | 143.91M | 265.79M | 104.97M | 181.28M |
| EffectOfExchangeRateChanges | 15.00K | -23.00K | -292.00K | 284.00K |
| ChangesInCash | -54.50M | -121.85M | 161.11M | -76.60M |
| FinancingCashFlow | 400.24M | 281.63M | 558.34M | 233.61M |
| CashFlowFromContinuingFinancingActivities | 400.24M | 281.63M | 558.34M | 233.61M |
| NetOtherFinancingCharges | -1.13M | 96.96M | 192.76M | -339.00K |
| ProceedsFromStockOptionExercised | -2.04M | 73.38M | 6.39M | -542.00K |
| NetCommonStockIssuance | 400.56M | 111.36M | 100.56M | 60.43M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 400.56M | 111.36M | 100.56M | 60.43M |
| NetIssuancePaymentsOfDebt | 2.86M | -64.00K | 258.62M | 174.07M |
| NetShortTermDebtIssuance | 2.88M | 0.00 | 0.00 | 174.12M |
| ShortTermDebtIssuance | 2.88M | 0.00 | 0.00 | 174.12M |
| NetLongTermDebtIssuance | -28.00K | -64.00K | 258.62M | 174.07M |
| LongTermDebtPayments | -28.00K | -64.00K | -77.00K | -58.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | 258.70M | 174.12M |
| InvestingCashFlow | -149.80M | -12.25M | -30.47M | 27.30M |
| CashFlowFromContinuingInvestingActivities | -149.80M | -12.25M | -30.47M | 27.30M |
| NetOtherInvestingChanges | -1.00M | |||
| NetInvestmentPurchaseAndSale | -145.55M | -4.36M | 114.00K | 127.69M |
| SaleOfInvestment | 95.82M | 136.61M | 10.47M | 162.00M |
| PurchaseOfInvestment | -241.37M | -140.97M | -10.36M | -34.31M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -1.00M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -1.00M | 0.00 |
| NetIntangiblesPurchaseAndSale | -406.00K | 0.00 | 0.00 | -21.23M |
| PurchaseOfIntangibles | -406.00K | 0.00 | 0.00 | -21.23M |
| NetPPEPurchaseAndSale | -3.85M | -6.89M | -30.58M | -78.16M |
| SaleOfPPE | 0.00 | 0.00 | 20.50M | |
| PurchaseOfPPE | -3.85M | -6.89M | -30.58M | -78.16M |
| OperatingCashFlow | -304.94M | -391.24M | -366.76M | -337.51M |
| CashFlowFromContinuingOperatingActivities | -304.94M | -391.24M | -366.76M | -337.51M |
| ChangeInWorkingCapital | -54.33M | -19.42M | 3.83M | -8.00M |
| ChangeInOtherWorkingCapital | 477.00K | 763.00K | -1.13M | -1.23M |
| ChangeInOtherCurrentLiabilities | -7.21M | -5.47M | -2.98M | -4.32M |
| ChangeInOtherCurrentAssets | 803.00K | -1.11M | 1.76M | 2.00M |
| ChangeInPayablesAndAccruedExpense | 2.99M | -4.67M | 213.00K | 12.10M |
| ChangeInAccruedExpense | 3.18M | -1.51M | 6.69M | 4.10M |
| ChangeInPayable | -190.00K | -3.17M | -6.48M | 8.00M |
| ChangeInAccountPayable | -190.00K | -3.17M | -6.48M | 8.00M |
| ChangeInPrepaidAssets | -4.86M | 1.70M | 5.96M | -16.56M |
| ChangeInInventory | -6.33M | -8.27M | 0.00 | 0.00 |
| ChangeInReceivables | -40.21M | -2.36M | 0.00 | 0.00 |
| ChangesInAccountReceivables | -40.21M | -2.36M | 0.00 | 0.00 |
| OtherNonCashItems | 90.58M | 24.13M | 93.64M | 35.31M |
| StockBasedCompensation | 36.81M | 34.43M | 49.16M | 40.18M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 632.00K | 1.59M | 4.19M |
| AssetImpairmentCharge | 14.02M | 0.00 | 886.00K | 2.01M |
| AmortizationOfSecurities | -2.75M | -1.49M | -137.00K | 1.32M |
| DeferredTax | -4.00K | -8.00K | ||
| DeferredIncomeTax | -4.00K | -8.00K | ||
| DepreciationAmortizationDepletion | 15.53M | 17.55M | 18.51M | 18.26M |
| DepreciationAndAmortization | 15.53M | 17.55M | 18.51M | 18.26M |
| OperatingGainsLosses | -53.32M | -33.43M | 49.61M | -13.46M |
| EarningsLossesFromEquityInvestments | 803.00K | |||
| GainLossOnInvestmentSecurities | -53.32M | -33.43M | 49.61M | -13.46M |
| NetIncomeFromContinuingOperations | -351.47M | -413.64M | -583.85M | -417.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IBRX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|